The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
Open accessAbstract
Background: Dopamine agonist resistance in prolactinoma is an infrequent phenomenon. Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (PRL) secretion and reducing tumor size in prolactinomas. The clinical presentation, management, and outcome of patients that are not well controlled by such commonly used doses of CAB-resistant patients are poorly understood. Design and methods: A multicenter retrospective study was designed to collect a large series of resistant prolactinoma patients, defined by uncontrolled hyperprolactinemia on CAB ≥2.0 mg weekly. Results: Ninety-two patients (50 F, 42 M) were analyzed. At diagnosis, most had macroprolactinomas (82.6%); males were significantly older than females (P=0.0003) and presented with a more aggressive disease. A genetic basis was identified in 12 patients. Thirty-six patients (39.1%) received only medical therapy, most underwent surgery (60.9%, including multiple interventions in 10.9%), and 14.1% received postoperative radiotherapy. Eight patients developed late CAB resistance (8.7%). The median maximal weekly dose of CAB (CAB max/w) was 3.5 mg (2.0–10.5). Despite a higher CAB max/w in patients treated with multimodal therapy (P=0.003 vs exclusive pharmacological treatment), a debulking effect of surgery was shown in 14 patients, with a higher rate of PRL control (P=0.006) and a significant reduction in CAB max/w (P=0.001) postoperatively. At last follow-up (median 88 months), PRL normalization and tumor disappearance were achieved in 28 and 19.9% of the patients respectively, with no significant sex-related difference observed in CAB max/w or disease control. Mortality was 4.8%, with four patients developing aggressive tumors (4.3%) and three a pituitary carcinoma (3.3%). Conclusion: CAB-resistant prolactinomas remain a serious concern. Surgical debulking, newer therapeutic strategies, and early diagnosis of genetic forms could help to improve their outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479
Cited by
Briet, C., Salenave, S., Bonneville, J.-F., Laws, E. R., & Chanson, P. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1042 · Cited by 409
Self-citationPetersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Self-citationKisspeptin Overcomes GnRH Neuronal Suppression Secondary to Hyperprolactinemia in Humans
Hoskova, K., Kayton Bryant, N., Chen, M. E., Nachtigall, L. B., Lippincott, M. F., Balasubramanian, R., & Seminara, S. B. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac166 · Cited by 39
Antiprolactinoma Effect of Hordenine by Inhibiting MAPK Signaling Pathway Activation in Rats
Wang, X., Guo, R.-Z., Ma, L., Ding, Q.-Y., Meng, J.-H., Chen, Y.-G., & Wu, J.-H. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/3107290 · Cited by 6
Metadata
- Authors
- Vroonen, L., Jaffrain-Rea, M.-L., Petrossians, P., Tamagno, G., Chanson, P., Vilar, L., Borson-Chazot, F., Naves, L. A., Brue, T., Gatta, B., Delemer, B., Ciccarelli, E., Beck-Peccoz, P., Caron, P., Daly, A. F., & Beckers, A.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11
- Volume
- 167
- Issue
- 5
- Pages
- 651-662
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2123338693
- Cited by
- 209
- References
- 2
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. https://app.cochat.ai/papers/10.1530/eje-12-0236
- The paper
- Vroonen, L., Jaffrain-Rea, M.-L., Petrossians, P., Tamagno, G., Chanson, P., Vilar, L., Borson-Chazot, F., Naves, L. A., Brue, T., Gatta, B., Delemer, B., Ciccarelli, E., Beck-Peccoz, P., Caron, P., Daly, A. F., & Beckers, A. (2012). Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology. https://doi.org/10.1530/eje-12-0236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.